Furong Li1, Chunxia Zheng2, Yongzhong Zhong1, Caihong Zeng1, Feng Xu1, Ru Yin1, Qi Jiang1, Minlin Zhou1, Zhihong Liu2. 1. National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China. 2. National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China springrosycloud@126.com liuzhihong@nju.edu.cn.
Abstract
BACKGROUND AND OBJECTIVES: Soluble urokinase plasminogen activator receptor (suPAR) was initially proposed as a pathogenic and predictive biomarker of primary FSGS, but the findings were controversial. This study aimed to clarify the clinical implications of suPAR. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study enrolled 109 patients with biopsy-proven primary FSGS who were administered prednisone between January 2011 and May 2013 and followed up for 6-24 months (median duration of follow-up, 12 months). Ninety-six healthy volunteers, 20 patients with minimal-change disease (MCD), and 22 patients with membranous nephropathy (MN) served as controls. Serum suPAR levels were measured using ELISA. RESULTS: suPAR levels in patients with FSGS (median, 3512 [interquartile range (IQR), 2232-4231] pg/ml) were significantly higher than in healthy controls (median, 1823 [IQR, 1563-2212] pg/ml; P<0.001), patients with MCD (median, 1678 [IQR, 1476-2182] pg/ml; P<0.001), and patients with MN (median, 1668 [IQR, 1327-2127] pg/ml; P<0.001). With 3000 pg/ml used as a threshold, suPAR levels were elevated in 48.6% of patients with FSGS, in contrast to 5% of patients with MCD and 4.5% of those with MN. suPAR levels were independently associated with steroid response in patients with FSGS (odds ratio, 85.02; P=0.001). Patients who were sensitive to steroids had significantly higher suPAR levels than nonsensitive patients (median, 3426 [IQR, 2670-5655] pg/ml versus 2523 [IQR, 1977-3460] pg/ml; P=0.001). A suPAR level of 3400 pg/ml was chosen as the optimal cutoff value for steroid response. At the 6-month follow-up in 84 patients with FSGS, suPAR levels were significantly decreased in those with suPAR level ≥ 3400 pg/ml (median, 4553 [IQR, 3771-6120] pg/ml versus 3149 [IQR, 2278-3953]; P=0.002) but were unchanged in patients with suPAR level <3400 pg/ml (median, 2359 [IQR, 2023-2842] pg/ml versus 2490 [IQR, 1916-3623] pg/ml; P=0.09). CONCLUSIONS: suPAR is specifically elevated in some patients with FSGS, which differs from the finding in patients with MCD and MN. A suPAR assay may help predict steroid response in patients with primary FSGS.
BACKGROUND AND OBJECTIVES: Soluble urokinase plasminogen activator receptor (suPAR) was initially proposed as a pathogenic and predictive biomarker of primary FSGS, but the findings were controversial. This study aimed to clarify the clinical implications of suPAR. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study enrolled 109 patients with biopsy-proven primary FSGS who were administered prednisone between January 2011 and May 2013 and followed up for 6-24 months (median duration of follow-up, 12 months). Ninety-six healthy volunteers, 20 patients with minimal-change disease (MCD), and 22 patients with membranous nephropathy (MN) served as controls. Serum suPAR levels were measured using ELISA. RESULTS:suPAR levels in patients with FSGS (median, 3512 [interquartile range (IQR), 2232-4231] pg/ml) were significantly higher than in healthy controls (median, 1823 [IQR, 1563-2212] pg/ml; P<0.001), patients with MCD (median, 1678 [IQR, 1476-2182] pg/ml; P<0.001), and patients with MN (median, 1668 [IQR, 1327-2127] pg/ml; P<0.001). With 3000 pg/ml used as a threshold, suPAR levels were elevated in 48.6% of patients with FSGS, in contrast to 5% of patients with MCD and 4.5% of those with MN. suPAR levels were independently associated with steroid response in patients with FSGS (odds ratio, 85.02; P=0.001). Patients who were sensitive to steroids had significantly higher suPAR levels than nonsensitive patients (median, 3426 [IQR, 2670-5655] pg/ml versus 2523 [IQR, 1977-3460] pg/ml; P=0.001). A suPAR level of 3400 pg/ml was chosen as the optimal cutoff value for steroid response. At the 6-month follow-up in 84 patients with FSGS, suPAR levels were significantly decreased in those with suPAR level ≥ 3400 pg/ml (median, 4553 [IQR, 3771-6120] pg/ml versus 3149 [IQR, 2278-3953]; P=0.002) but were unchanged in patients with suPAR level <3400 pg/ml (median, 2359 [IQR, 2023-2842] pg/ml versus 2490 [IQR, 1916-3623] pg/ml; P=0.09). CONCLUSIONS:suPAR is specifically elevated in some patients with FSGS, which differs from the finding in patients with MCD and MN. A suPAR assay may help predict steroid response in patients with primary FSGS.
Authors: Wen Y Ding; Ania Koziell; Hugh J McCarthy; Agnieszka Bierzynska; Murali K Bhagavatula; Jan A Dudley; Carol D Inward; Richard J Coward; Jane Tizard; Christopher Reid; Corinne Antignac; Olivia Boyer; Moin A Saleem Journal: J Am Soc Nephrol Date: 2014-02-07 Impact factor: 10.121
Authors: Franz Schaefer; Howard Trachtman; Elke Wühl; Marietta Kirchner; Salim S Hayek; Ali Anarat; Ali Duzova; Sevgi Mir; Dusan Paripovic; Alev Yilmaz; Francesca Lugani; Klaus Arbeiter; Mieczyslaw Litwin; Jun Oh; Maria Chiara Matteucci; Jutta Gellermann; Simone Wygoda; Augustina Jankauskiene; Günter Klaus; Jiri Dusek; Sara Testa; Aleksandra Zurowska; Alberto Caldas Afonso; Melissa Tracy; Changli Wei; Sanja Sever; William Smoyer; Jochen Reiser Journal: JAMA Pediatr Date: 2017-11-06 Impact factor: 16.193
Authors: Crislaine Aparecida da Silva; Liliane Silvano Araújo; Maria Luíza Gonçalves Dos Reis Monteiro; Lívia Helena de Morais Pereira; Marcos Vinícius da Silva; Lúcio Roberto Cançado Castellano; Rosana Rosa Miranda Corrêa; Marlene Antônia Dos Reis; Juliana Reis Machado Journal: Dis Markers Date: 2019-05-02 Impact factor: 3.434
Authors: Jiwon M Lee; Jae Won Yang; Andreas Kronbichler; Michael Eisenhut; Gaeun Kim; Keum Hwa Lee; Jae Il Shin Journal: J Immunol Res Date: 2019-04-04 Impact factor: 4.818